Novel Treatment Shows Early Promise for Gastric Cancer

A novel antibody acting on both PD-1 and CTLA4 has shown activity in first-line treatment of gastric and gastroesophageal junction cancer.

Related Keywords

Beijing ,China ,Peking ,Chinese ,Akeso Biopharma ,Jiafu Ji ,Katherine Bever ,Johns Hopkins University ,University Cancer Hospital ,Institute Gastrointestinal Cancer Center ,Cancers Symposium ,Peking University Cancer Hospital ,Noncolorectal Gastrointestinal Cancer ,Oncolorectal Gi Cancer ,Gastric Cancer ,Alignant Stomach Neoplasm ,Cancer ,Alignant Neoplasia ,Arcinoma ,Chemotherapy ,Cervical Cancer ,Alignant Cervix Neoplasm ,Gastrointestinal Malignancy ,I Malignancy ,Toxicology ,Clinical Research ,Clinical Trials ,Linical Studies ,Combination Chemotherapy ,